AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01593969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard RUTF
Description: Standard formulation RUTF given according to National Guidelines
Study NCT01491633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 140 mg orally, daily in 28 day cycles
Study NCT02650141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziyinxiehuo Granules
Description: Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper
Study NCT02650141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zishenqinggan Granules
Description: Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper
Study NCT03669068 — intervention group
Intervention type: PROCEDURE
Intervention: Gastrointestinal endoscopy
Description: Two separated groups will be included in the registry:~1. Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~2. Patients undergoing elective gastrointestinal endoscopy.
Study NCT02724085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
Study NCT03085225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of trabectedin with durvalumab
Description: Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).~Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial.
Study NCT02044250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75mg 1tab P.O. daily
Study NCT02044250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100\~200mg 1\~2tab P.O. daily
Study NCT04325854 — intervention group
Intervention type: PROCEDURE
Intervention: I and II level ART procedure
Description: I level: Intrauterine insemination II level: Invitro fertilization technique; Intracytoplasmic sperm injection; Embryo transfer
Study NCT03698708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARES Intervention
Description: A group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.
Study NCT02604576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC Bromopride 10 mg and Simethicone 80 mg
Description: Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
Study NCT02604576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromopride 10 mg
Description: Bromopride 10 mg
Study NCT02744521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom-based screening intervention
Description: The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
Study NCT02652936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AF-130
Description: AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
Study NCT02652936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: AF-130 matching placebo capsule
Study NCT02018224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-to-end suturation without augmentation
Description: End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
Study NCT01222949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim
Description: Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
Study NCT02018224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-to-end suturation with augmentation.
Description: End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
Study NCT02026778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ondansetron
Description: The ondansetron group is given placebo (pyridoxin) instead of betahistine.~The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.
Study NCT02026778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron-betahistine
Description: The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.~The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.
Study NCT06406972 — intervention group
Intervention type: OTHER
Intervention: Brief Admission by self-referral (BA)
Description: Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.
Study NCT04154241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR scan
Description: The PET will be performed with (68Ga)-labeled somatostatin analogue since it was proven to be superior to other NET PET tracers in terms of lesion detection and sensitivity \[11\] \[12\]. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, diffusion-weighted images with multiple b values and apparent diffusion coefficient (ADC) maps.~All images will be analyzed with big data tools such as radiomics and texture analysis in order to integrate all image parameters and different contrasts into individual tumor status. Then, accuracy, sensitivity and specificity will be evaluated by correlation of this data collection and analysis method with histological biomarkers (for example, Ki67 level) and treatment results.
Study NCT00860717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment
Description: Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
Study NCT00860717 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Description: The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact.
Study NCT01141322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
Study NCT01141322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
Study NCT03292315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1MG Injection [Ozempic]
Description: Once weekly injection of 1mg of Semaglutide.
Study NCT03292315 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No injection will be administered
Study NCT01752465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
Study NCT01752465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coaching
Description: Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
Study NCT01752465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
Study NCT02577198 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medilogy Decision Support System (MediDSS)
Description: Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
Study NCT02577198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medilogy Decision Support System (MediDSS)
Description: Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
Study NCT01277445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotic
Description: Inulin-fructan 15mg/day for 28days
Study NCT01277445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotic
Description: Daily consumption of 15g inulin-fructan for 28 days
Study NCT03777657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg IV on Day 1 during each 21-day cycle
Study NCT03777657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match tislelizumab on Day 1 during each 21-day cycle
Study NCT01277445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: Daily consumption of 15g inulin-fructan for 28 days
Study NCT02498769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
Study NCT03776734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy application
Description: Effects of 5-10- 20 minutes cold application on quadriceps muscle
Study NCT01164215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
Study NCT01164215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
Study NCT01164215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2, intravenously for 2 hours, once every 2 weeks
Study NCT00618033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: varying concentration of glucose in dialysate
Study NCT02498769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03105934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients with Pulmonary Arterial Hypertension
Description: 2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
Study NCT01776567 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stents
Study NCT05925244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Condition
Description: Control (no alteration to body mass).
Study NCT05925244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: +12% Body Mass
Description: Loaded walking exercise (12% increase in body mass using a weighted vest).
Study NCT05925244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: -12% Body Mass
Description: Unloaded walking exercise (12% decrease in body mass using lower body positive pressure).
Study NCT04030663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: papaverine
Description: periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
Study NCT04030663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerine
Description: periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
Study NCT03777657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m² IV on Day 1 during each 21-day cycle
Study NCT04030663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: xlyocaine
Description: periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
Study NCT01253317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1
Description: 1) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
Study NCT01459263 — intervention group
Intervention type: DEVICE
Intervention: ClariVein
Description: Using the ClariVein device, the GSV will be occluded.
Study NCT04598360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart-Lung-Machine
Description: blood sample before and during a single Heart-Lung-Machine procedure